Abstract
Since the landmark multicenter trial in type I diabetics by Lewis et al. in 1993 ([1][1]), the use of angiotensin-converting enzyme (ACE) inhibitors to retard progression of diabetic nephropathy has become a widely accepted therapeutic strategy. Although initial animal studies determined that ACE
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
